This inventor holds 3 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Kyoto University, National Cancer Center, Takeda Pharmaceutical Company Limited. Active years: 2020-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:



Years Active: 2020-2025
Title: Atsutaka Minagawa: Innovator in Cell-Based Immunotherapy
Introduction
Atsutaka Minagawa is a prominent inventor based in Kyoto, Japan. He has made significant contributions to the field of immunotherapy, particularly in the development of methods for inducing T cells from pluripotent stem cells. With a total of 3 patents to his name, Minagawa's work is paving the way for advancements in cancer treatment.
Latest Patents
Minagawa's latest patents include a method for inducing T cells for cell-based immunotherapy from pluripotent stem cells. This innovative method comprises several steps aimed at enhancing the efficacy of T cell therapies. Additionally, he has developed T cell receptors capable of binding to specific peptides, which are crucial for targeting cancers associated with glypican-3 expression. These advancements hold promise for improving treatment outcomes for patients with certain types of cancer.
Career Highlights
Throughout his career, Atsutaka Minagawa has been associated with esteemed institutions such as Kyoto University and Thyas Co. Ltd. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in immunotherapy.
Collaborations
Minagawa has worked alongside notable colleagues, including Shin Kaneko and Yutaka Yasui. Their combined expertise has fostered an environment of innovation and discovery, further enhancing the impact of their research.
Conclusion
Atsutaka Minagawa's contributions to cell-based immunotherapy exemplify the potential of innovative research in combating cancer. His patents and collaborations reflect a commitment to advancing medical science and improving patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile